TAK-861 placebo (same excipients as TAK-861)
Sponsors
Takeda Development Center Americas Inc.
Conditions
Narcolepsy with Cataplexy (Narcolepsy Type 1)
Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)
CompletedCTIS2023-508465-32-00
Start: 2024-09-03End: 2025-06-03Target: 85Updated: 2025-04-02
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)
CompletedCTIS2024-511998-30-00
Start: 2024-10-18End: 2025-05-30Target: 80Updated: 2025-04-07